<DOC>
	<DOCNO>NCT02063659</DOCNO>
	<brief_summary>The purpose study evaluate effect telotristat etiprate versus placebo incidence treatment-emergent adverse event 5-hydroxyindoleacetic acid ( 5-HIAA ) level .</brief_summary>
	<brief_title>Telotristat Etiprate Carcinoid Syndrome Therapy</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<criteria>Patients ≥ 18 year age All patient reproductive potential must agree use adequate method contraception study 12 week Followup visit . Histopathologicallyconfirmed , welldifferentiated metastatic neuroendocrine tumor Documented history carcinoid syndrome Patient able willing provide write informed consent prior participation Presence diarrhea attribute condition carcinoid syndrome . Presence 12 watery bowel movement per day Positive stool examination enteric pathogen , pathogenic ovum parasite , Clostridium difficile Screening Karnofsky Performance Status ≤ 60 % Presence clinically significant laboratory , medical history , physical examination finding deem unacceptable Investigator A history short bowel syndrome History constipation within 2 year Screening Life expectancy &lt; 12 month Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>